000137252 001__ 137252
000137252 005__ 20240321220221.0
000137252 0247_ $$2doi$$a10.1016/j.psyneuen.2013.09.026
000137252 0247_ $$2pmid$$apmid:24275006
000137252 0247_ $$2ISSN$$a0306-4530
000137252 0247_ $$2ISSN$$a1873-3360
000137252 0247_ $$2altmetric$$aaltmetric:1842281
000137252 037__ $$aDZNE-2020-03574
000137252 041__ $$aEnglish
000137252 082__ $$a610
000137252 1001_ $$0P:(DE-HGF)0$$aStriepens, Nadine$$b0
000137252 245__ $$aOxytocin enhances attractiveness of unfamiliar female faces independent of the dopamine reward system.
000137252 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2014
000137252 264_1 $$2Crossref$$3print$$bElsevier BV$$c2014-01-01
000137252 3367_ $$2DRIVER$$aarticle
000137252 3367_ $$2DataCite$$aOutput Types/Journal article
000137252 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1705997990_18608
000137252 3367_ $$2BibTeX$$aARTICLE
000137252 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000137252 3367_ $$00$$2EndNote$$aJournal Article
000137252 520__ $$aEvidence from animal studies suggests that the social attraction and bonding effects of the neuropeptide oxytocin (OXT) are mediated by its modulation of dopamine (DA) release in brain reward centers, but this has not yet been demonstrated in humans. DA release can be measured by positron emission tomography (PET) using the radioligand [11C]raclopride. Its binding to DA D2 receptors (D2R) is sensitive and reciprocally related to endogenous DA, especially in the striatum. In a randomized double-blind placebo-controlled within-subjects trial on 18 adult male volunteers we combined [11C]raclopride PET and a facial attractiveness rating task to establish whether intranasal OXT (24 IU) increased both the perceived attractiveness of unfamiliar female faces and striatal DA release compared with placebo administration. While our behavioral data confirmed that subjects rated unfamiliar female faces as more attractive following OXT treatment, and this correlated with an increased perfusion rate in the striatum, there was no evidence for altered [11C]raclopride binding in the striatum or pallidum. Instead under OXT we rather observed an increased [11C]raclopride binding and reduced perfusion rate in subregions of the right dorsomedial prefrontal gyrus and superior parietal gyrus. The absence of OXT effects on dopamine release and D2 receptors in brain reward centers, despite increased striatal activity, implies that the peptide may facilitate perceived attraction via non-dopaminergic actions.
000137252 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000137252 542__ $$2Crossref$$i2014-01-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000137252 588__ $$aDataset connected to CrossRef, PubMed,
000137252 650_7 $$0430K3SOZ7G$$2NLM Chemicals$$aRaclopride
000137252 650_7 $$050-56-6$$2NLM Chemicals$$aOxytocin
000137252 650_7 $$0VTD58H1Z2X$$2NLM Chemicals$$aDopamine
000137252 650_2 $$2MeSH$$aAdult
000137252 650_2 $$2MeSH$$aCorpus Striatum: diagnostic imaging
000137252 650_2 $$2MeSH$$aCorpus Striatum: drug effects
000137252 650_2 $$2MeSH$$aCorpus Striatum: metabolism
000137252 650_2 $$2MeSH$$aDopamine: metabolism
000137252 650_2 $$2MeSH$$aDouble-Blind Method
000137252 650_2 $$2MeSH$$aFace
000137252 650_2 $$2MeSH$$aFemale
000137252 650_2 $$2MeSH$$aHumans
000137252 650_2 $$2MeSH$$aMale
000137252 650_2 $$2MeSH$$aOxytocin: pharmacology
000137252 650_2 $$2MeSH$$aRaclopride: pharmacology
000137252 650_2 $$2MeSH$$aRadionuclide Imaging
000137252 7001_ $$0P:(DE-HGF)0$$aMatusch, Andreas$$b1
000137252 7001_ $$0P:(DE-HGF)0$$aKendrick, Keith M$$b2
000137252 7001_ $$0P:(DE-HGF)0$$aMihov, Yoan$$b3
000137252 7001_ $$0P:(DE-HGF)0$$aElmenhorst, David$$b4
000137252 7001_ $$0P:(DE-HGF)0$$aBecker, Benjamin$$b5
000137252 7001_ $$0P:(DE-HGF)0$$aLang, Markus$$b6
000137252 7001_ $$0P:(DE-HGF)0$$aCoenen, Heinz H$$b7
000137252 7001_ $$0P:(DE-2719)2000015$$aMaier, Wolfgang$$b8$$udzne
000137252 7001_ $$0P:(DE-HGF)0$$aHurlemann, René$$b9$$eCorresponding author
000137252 7001_ $$0P:(DE-HGF)0$$aBauer, Andreas$$b10
000137252 77318 $$2Crossref$$3journal-article$$a10.1016/j.psyneuen.2013.09.026$$b : Elsevier BV, 2014-01-01$$p74-87$$tPsychoneuroendocrinology$$v39$$x0306-4530$$y2014
000137252 773__ $$0PERI:(DE-600)1500706-6$$a10.1016/j.psyneuen.2013.09.026$$gVol. 39, p. 74 - 87$$p74-87$$q39<74 - 87$$tPsychoneuroendocrinology$$v39$$x0306-4530$$y2014
000137252 8564_ $$uhttps://pub.dzne.de/record/137252/files/DZNE-2020-03574_Restricted.pdf
000137252 8564_ $$uhttps://pub.dzne.de/record/137252/files/DZNE-2020-03574_Restricted.pdf?subformat=pdfa$$xpdfa
000137252 909CO $$ooai:pub.dzne.de:137252$$pVDB
000137252 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000015$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000137252 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000137252 9141_ $$y2014
000137252 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000137252 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPSYCHONEUROENDOCRINO : 2017
000137252 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000137252 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000137252 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000137252 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000137252 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000137252 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000137252 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000137252 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000137252 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000137252 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000137252 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000137252 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000137252 9201_ $$0I:(DE-2719)7000001$$kU Clinical Researchers - Bonn$$lU Clinical Researchers - Bonn$$x0
000137252 980__ $$ajournal
000137252 980__ $$aVDB
000137252 980__ $$aI:(DE-2719)7000001
000137252 980__ $$aUNRESTRICTED